Coastal Bridge Advisors LLC Acquires 1,500 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Coastal Bridge Advisors LLC raised its holdings in UroGen Pharma Ltd. (NASDAQ:URGN) by 4.1% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,500 shares of the company’s stock after buying an additional 1,500 shares during the quarter. Coastal Bridge Advisors LLC’s holdings in UroGen Pharma were worth $646,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD acquired a new stake in shares of UroGen Pharma in the first quarter worth $4,008,000. Superstring Capital Management LP acquired a new stake in UroGen Pharma in the 4th quarter worth $3,831,000. Point72 Asset Management L.P. grew its position in UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after purchasing an additional 1,337,257 shares during the last quarter. Oak Ridge Investments LLC bought a new position in shares of UroGen Pharma during the 1st quarter worth about $918,000. Finally, Sierra Summit Advisors LLC acquired a new position in shares of UroGen Pharma during the fourth quarter valued at about $218,000. 91.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

URGN has been the topic of several research reports. Oppenheimer boosted their price target on UroGen Pharma from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, June 14th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Wednesday, August 14th. Guggenheim initiated coverage on UroGen Pharma in a research report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price for the company. Finally, LADENBURG THALM/SH SH boosted their price target on shares of UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a report on Friday, June 14th.

UroGen Pharma Trading Up 1.2 %

URGN stock opened at $12.90 on Friday. UroGen Pharma Ltd. has a 1-year low of $10.60 and a 1-year high of $20.70. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. The business’s 50 day moving average is $14.42 and its 200-day moving average is $14.62. The firm has a market cap of $302.56 million, a P/E ratio of -3.79 and a beta of 1.11.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million during the quarter, compared to analysts’ expectations of $23.69 million. Equities analysts anticipate that UroGen Pharma Ltd. will post -3.49 earnings per share for the current fiscal year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.